RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sarepta Therapeutics (SRPT) PT Raised to $203 at Goldman Sachs
June 20, 2018 8:38 AM EDTGoldman Sachs raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $203.00 (from $127.00) while maintaining a Buy rating following the company's R&D day. SRPT reported highly encouraging preliminary Ph1/2 NCH micro-dystrophin gene therapy data from cohort B for the three initially-dosed patients... More
Sarepta Therapeutics (SRPT) PT Raised to $170 at BTIG
June 20, 2018 7:16 AM EDTBTIG raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $170.00 (from $120.00) while maintaining a Buy rating. Analyst Timothy Chiang continues to see SRPT as a disruptor in the Duchenne Muscular Dystrophy treatment market with its pipeline of gene therapy and RNA-splicing product... More
Sarepta Therapeutics (SRPT) DMD Gene Therapy Results 'Really Positive' - Baird
June 19, 2018 10:42 AM EDTBaird analyst Brian Skorney calls Sarepta Therapeutics (NASDAQ: SRPT) DMD gene therapy results "really positive."
Skorneycommented, "The initial results, in two patients, are beyond encouraging. We think this data could indicate levels of expression that could be functionally converting patients from a... More
Sarepta Therapeutics' (SRPT) Gene Therapy Shows Promising Early Results in DMD Study - Bloomberg
June 19, 2018 10:21 AM EDTPreliminary Phase 1/2a of Sarepta Therapeutics' (NASDAQ: SRPT) gene therapy for DMD showed an average of 38% of micro-dystrophin compared to normal utilizing its method of measurement. Analysts expectations were for a 10%-15% gain, according to Bloomberg.
... More